TREATMENT NON-ADHERENCE – A MAJOR FACTOR OF THERAPY FAILURE IN PATIENTS WITH SEVERE PSORIASIS
Abstract:
Systemic immunosuppressive therapy and/or anti-TNF-α, anti IL 12-23, anti IL 17 biological
treatments can improve the long-term prognosis of patients with moderate and severe forms of psoriasis.
Forgoing such treatments may be due to side effects that can occur during the treatment process, as well
as to patients’ noncompliance and non-adherence to treatment. As such, a relapse of the psoriasis can
occur - sometimes in even more severe forms than previously - as well other pathologies that are linked
to treatment complications. We present the case of a patient with a severe form of psoriasis vulgaris and
arthropathic psoriasis who, during disease evolution, received alternative systemic treatment with
Methotrexate, Acitretin and Cyclosporine, as well as biological therapy with Infliximab. The evolution of
the disease in this case can be described as fluctuating, due to either treatment noncompliance, or to
medication related-side effects. Based on this clinical case, we have reviewed relevant literature sources
documenting chronic treatment adherence, successes in psoriasis and the factors related to the patient
or medication administered that influences the therapeutic success.
full text article in English (.EN) |